# JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC

> **NCT07714304** · NA · NOT_YET_RECRUITING · sponsor: **Huan Zhou** · enrollment: 20 (estimated)

## Conditions studied

- NSCLC Harboring EGFR Mutations

## Interventions

- **DRUG:** JS212 for Injection
- **DRUG:** JS111 capsules (AP-L1898)

## Key facts

- **NCT ID:** NCT07714304
- **Lead sponsor:** Huan Zhou
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2026-11-13
- **Final completion:** 2029-07-23
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07714304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07714304, "JS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07714304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*